RYALTRIS is a fixed-dose combination therapy that provides relief for the symptoms of SAR, both nasal and ocular, in one easy-to-use nasal spray
This launch builds upon Hikma’s leading position as one of the largest US providers of nasally administered medicines used for treating seasonal allergies and advances its objective of growing its specialty business in the US
Glenmark continues to cooperate with the US FDA and is committed to undertake all necessary steps required to address their observations at the earliest.
The company continues to cooperate with the US FDA and is committed to undertake all necessary steps required to address their observations at the earliest
These medicines have low risk of hypoglycemia, provide beta cell protection, offer cardio-renal benefits and are safe for patients with kidney or liver conditions and senior citizens
The company is committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe.
Glenmark is the first company in India to market the innovative FDC of Indacaterol
'Hello Skin' has been developed in collaboration with the IADVL (Indian Association of Dermatologists, Venereologists and Leprologists)
According to IQVIA sales data for the 12-month period ending March 2022, the Zytiga tablets, 500 mg market achieved annual sales of approximately US $ 260.2 million
Glenmark's current portfolio consists of 174 products authorized for distribution in the U.S. marketplace and 48 ANDA's pending approval with the USFDA
Subscribe To Our Newsletter & Stay Updated
